Notice: This company has been marked as potentially delisted and may not be actively trading. Vaccitech (VACC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesInsider TradesOwnershipTrends VACC vs. ZNTL, NLTX, CKPT, SLN, MNPR, IFRX, PBYI, CRBP, BMEA, and VTYXShould you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include Zentalis Pharmaceuticals (ZNTL), Neoleukin Therapeutics (NLTX), Checkpoint Therapeutics (CKPT), Silence Therapeutics (SLN), Monopar Therapeutics (MNPR), InflaRx (IFRX), Puma Biotechnology (PBYI), Corbus Pharmaceuticals (CRBP), Biomea Fusion (BMEA), and Ventyx Biosciences (VTYX). These companies are all part of the "pharmaceutical preparations" industry. Vaccitech vs. Zentalis Pharmaceuticals Neoleukin Therapeutics Checkpoint Therapeutics Silence Therapeutics Monopar Therapeutics InflaRx Puma Biotechnology Corbus Pharmaceuticals Biomea Fusion Ventyx Biosciences Vaccitech (NASDAQ:VACC) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations. Does the media refer more to VACC or ZNTL? In the previous week, Zentalis Pharmaceuticals had 25 more articles in the media than Vaccitech. MarketBeat recorded 25 mentions for Zentalis Pharmaceuticals and 0 mentions for Vaccitech. Zentalis Pharmaceuticals' average media sentiment score of 0.02 beat Vaccitech's score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Vaccitech Neutral Zentalis Pharmaceuticals Neutral Is VACC or ZNTL more profitable? Zentalis Pharmaceuticals has a net margin of 0.00% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vaccitech-409.18% -23.41% -20.85% Zentalis Pharmaceuticals N/A -43.91%-34.96% Do insiders & institutionals believe in VACC or ZNTL? 26.1% of Vaccitech shares are owned by institutional investors. 6.0% of Vaccitech shares are owned by insiders. Comparatively, 3.6% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor VACC or ZNTL? Zentalis Pharmaceuticals received 43 more outperform votes than Vaccitech when rated by MarketBeat users. However, 70.83% of users gave Vaccitech an outperform vote while only 62.50% of users gave Zentalis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVaccitechOutperform Votes1770.83% Underperform Votes729.17% Zentalis PharmaceuticalsOutperform Votes6062.50% Underperform Votes3637.50% Which has more volatility and risk, VACC or ZNTL? Vaccitech has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Do analysts rate VACC or ZNTL? Zentalis Pharmaceuticals has a consensus price target of $8.58, indicating a potential upside of 416.73%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Vaccitech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccitech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Zentalis Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44 Which has higher earnings and valuation, VACC or ZNTL? Vaccitech has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaccitech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaccitech$13.42M2.73$5.34M-$1.43-0.66Zentalis PharmaceuticalsN/AN/A-$292.19M-$2.49-0.67 SummaryVaccitech beats Zentalis Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Vaccitech News Delivered to You Automatically Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VACC vs. The Competition Export to ExcelMetricVaccitechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.62M$6.90B$5.61B$9.12BDividend YieldN/A2.95%5.36%3.98%P/E Ratio-0.6610.0389.5417.51Price / Sales2.73348.831,227.0083.27Price / Cash19.3065.0944.3037.67Price / Book0.155.295.124.72Net Income$5.34M$154.95M$117.78M$224.62M Vaccitech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VACCVaccitechN/A$0.95+2.2%N/A-65.4%$36.62M$13.42M-0.6633Gap UpZNTLZentalis Pharmaceuticals1.9456 of 5 stars$2.24-6.3%$10.00+346.4%-85.6%$159.62MN/A-0.90160Analyst ForecastOptions VolumeNews CoverageHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$16.60-5.8%N/A-51.2%$156.01MN/A-5.3490News CoverageHigh Trading VolumeCKPTCheckpoint Therapeutics3.8441 of 5 stars$3.18-4.5%$12.00+277.4%+42.7%$155.28M$100,000.00-1.7310Short Interest ↑Gap DownSLNSilence Therapeutics2.7204 of 5 stars$5.12+1.8%$57.20+1,017.2%-72.3%$153.24M$31.55M-3.26100Analyst ForecastNews CoverageHigh Trading VolumeMNPRMonopar Therapeutics1.2748 of 5 stars$28.54-6.4%$38.50+34.9%+2,055.6%$150.69MN/A-14.4910IFRXInflaRx2.406 of 5 stars$2.54-0.4%$8.00+215.0%+30.2%$149.56M$70,000.00-2.3560Short Interest ↑PBYIPuma Biotechnology4.2453 of 5 stars$2.97-1.7%$7.00+135.7%-38.4%$145.79M$243.57M6.19200Analyst RevisionPositive NewsCRBPCorbus Pharmaceuticals4.0412 of 5 stars$11.92-9.1%$62.00+420.1%-48.3%$145.19MN/A-2.5440Short Interest ↓BMEABiomea Fusion2.6273 of 5 stars$3.97-2.2%$39.36+891.5%-76.6%$143.87MN/A-0.9950Short Interest ↑VTYXVentyx Biosciences3.6237 of 5 stars$2.02+6.9%$10.00+395.0%-8.5%$142.83MN/A-0.8630Short Interest ↓Gap Down Related Companies and Tools Related Companies Zentalis Pharmaceuticals Competitors Neoleukin Therapeutics Competitors Checkpoint Therapeutics Competitors Silence Therapeutics Competitors Monopar Therapeutics Competitors InflaRx Competitors Puma Biotechnology Competitors Corbus Pharmaceuticals Competitors Biomea Fusion Competitors Ventyx Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VACC) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredDonald Trump is about to free crypto from its chains …On October 25th, Juan said Bitcoin would cross $100,000 before the inauguration. Now he thinks it could rea...Weiss Ratings | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredTrillion-Dollar Crypto PlayPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccitech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
